Jorge Mestre-Ferrándiz, Agustín Rivero, Alejandro Orrico-Sánchez, Álvaro Hidalgo, Fernando Abdalla, Isabel Martín, Javier Álvarez, Manuel García-Cenoz, Maria Del Carmen Pacheco, María Garcés-Sánchez, Néboa Zozaya, Raúl Ortiz-de-Lejarazu
BACKGROUND: Respiratory syncytial virus (RSV) is a highly infectious disease that poses a significant clinical and medical burden, as well as social disruption and economic costs, recognized by the World Health Organization as a public health issue. After several failed attempts to find preventive candidates (compounds, products, including vaccines), new alternatives might be available, one being nirsevimab, the first and only option approved for RSV prevention in neonates and infants during their first RSV season...
January 18, 2024: BMC Infectious Diseases